Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients
المؤلفون المشاركون
Nie, Keke
Jiang, Haiping
Zhang, Chunling
Geng, Chuanxin
Xu, Xiajuan
Zhang, Ling
Zhang, Hao
Zhang, Zhongfa
Lan, Ketao
Ji, Youxin
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-03-11
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Purpose.
To identify the somatic mutated genes for optimal targets of non-small-cell lung cancer after resistance to osimertinib treatment.
Patients and Methods.
Study patients all had advanced lung adenocarcinoma and acquired resistance to osimertinib as a second- or third-line treatment.
These patients had harboring EGFR T790M mutation before osimertinib treatment, which was confirmed by Amplification Refractory Mutation System (ARMS) PCR or Next-Generation Sequencing (NGS).
After resistance to osimertinib treatment, tumor tissue was collected by core needle biopsy.
DNA was extracted from 15 × 5 um sliced section of formalin-fixed paraffin-embedded (FFPE) material and NGS was done.
The genetic changes were analyzed.
Results.
A total of 9 Chinese patients were studied, 5 females and 4 males, age 51–89 years.
After progression with osimertinib treatment, core needle biopsy was performed and next-generation sequencing was performed.
Nine patients had harboring 62 point mutations, 2 altered gene copies, 2 amplifications, and 1 EML4-ALK gene fusion.
No MET or HER2 amplification was found in this cohort study.
Nine patients still maintained initial EGFR 19 del or L858R activating mutations, while 7 of them kept EGFR T790M mutations.
Among the 7 patients, 5 had secondary EGFR C797S and/or C797G mutations, which all happened in the same allele with T790M mutation.
All patients were treated with targets therapies, chemotherapy, or best supportive care (BSC) in accordance with NGS genetic results and patients’ performance status; 7 of them are still alive and 2 of them died of disease progression at last follow-up.
Conclusions.
EGFR C797S/G mutation and the same one presented on the same allele with EGFR T790M mutation were the most common mutation feature and played a key role in resistance to osimertinib in Chinese patients with NSCLC.
Tumor cells losing T790M mutation and maintaining EGFR activating mutation might benefit from first-generation EGFR-TKI treatment.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Nie, Keke& Jiang, Haiping& Zhang, Chunling& Geng, Chuanxin& Xu, Xiajuan& Zhang, Ling…[et al.]. 2018. Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients. BioMed Research International،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1129429
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Nie, Keke…[et al.]. Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients. BioMed Research International No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1129429
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Nie, Keke& Jiang, Haiping& Zhang, Chunling& Geng, Chuanxin& Xu, Xiajuan& Zhang, Ling…[et al.]. Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1129429
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1129429
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر